Abstract: Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

Abstract: A processor-implemented method includes causing fluid delivery to a patient based on a first value for a control parameter, identifying a second value for the control parameter based on a determination that a current operational context is associated with the second value, and causing fluid delivery to the patient based on the second value for the control parameter in lieu of the first value for the control parameter.

Abstract: An infusion pump system and method with common line auto flush, wherein the infusion pump system has a first reservoir, a second reservoir, a junction, a common line having one end in fluid connection with the junction and having a terminal fluid delivery end, and an infusion pump. The method includes infusing the first fluid at a first rate along a first flow path; entering a common line flush volume value for the common line; switching from the first flow path to a second flow path; driving the second fluid at the first rate along the second flow path; monitoring volume of the second fluid driven at the first rate; and driving the second fluid at a second rate along the second flow path when the monitored volume is equal to or greater than the common line flush volume value.

Abstract: The disclosed tube securement device attaches to the patient's body and to the tube, while allowing for a section of the tube to be detached from the tube securement device. The tube securement device comprises a backing with adhesive coated sections. The backing comprises a first end section, a second end section, and a midsection, separating the first end section from the second end section. The tube securement device further comprises a first adhesive on at least a portion of the first major surface of the first end section, a second adhesive on at least a portion of the first major surface of the second end section, and wherein the first major surface of the midsection is free of tacky adhesive.

Abstract: A breast pump milk flow sensor system and apparatus for accurately assessing both a flow rate and amount of milk expressed during a pumping session is provided. The breast pump milk flow rate sensor system and apparatus may be contained within a breast pump.

Abstract: A microneedle assembly that is capable of transdermal delivery of a drug compound, such as a vaccine, (e.g., vaccine) across a dermal barrier of a subject (e.g., human), and/or detecting the presence of an analyte in the subject is provided. The microneedle assembly comprises a plurality of microneedles arranged on a support that each contain a tip and base, one or both of which are formed from a polymer composition that includes a liquid crystalline polymer. By selectively controlling the specific components of the polymer composition, as well as their relative concentration, the resulting microneedles may exhibit a high degree of physical alignment, which can help ensure better performance during use of the microneedle assembly.

Abstract: A blood glucose sensing system includes a plurality of physiological sensors. The system can estimate blood glucose based on discrete invasive blood glucose estimates from a blood sample, discrete noninvasive blood glucose estimates derived from optical sensors, and continuously-calculated blood glucose estimates derived from a nonlinear state-space model of glucose and insulin reactions within a human body. The state-space model has user-entered values corresponding to their insulin and meal intake. The user's blood glucose is estimated from a combination of the discrete invasive blood glucose estimates, the discrete noninvasive blood glucose estimates and the continuously-calculated blood glucose estimate.

Abstract: A patient monitoring system may include processing circuitry configured to receive an indication of a surgical event, obtain a nociception parameter of a patient, compare the nociception parameter of the patient to a nociception threshold to detect a nociception event, determine whether the surgical event corresponds to the nociception event, and in response to determinizing whether the surgical event corresponds to the nociception event, provide an indication to adjust an amount of analgesic administered to the patient.

Abstract: Disclosed herein are systems and methods for safely switching between medicament delivery control algorithms for control of an ambulatory infusion pump or other medical device. Infusion pumps and/or remote control devices may be capable of operating different algorithms for delivery of medicament and provided herein are mechanisms for safely transitioning between algorithms.

Abstract: An exoskeleton device is capable of being positioned over an expandable instrument, such as a balloon catheter. The exoskeleton device may include an expandable section that receives an expander of the expandable instrument. Expansion of the expander may cause the expandable section of the exoskeleton device to expand and force the expandable section of the exoskeleton device against a surface to be treated. The expandable section may be capable of scoring the surface against which it is forced.

Abstract: An insulin delivery monitoring system that includes an insulin delivery device and a controller configured to perform or control performance of operations. A method of insulin delivery include determining a correction dose of insulin and triggering an alert.

Abstract: The invention relates to a blood treatment device configured to remove anti-neutrophil cytoplasmic antibodies (ANCAs) from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix, and wherein said matrix comprises a monomeric form of proteinase 3 (PR3). The invention further relates to an extra-corporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating a medical condition associated with ANCA.

Abstract: A device for delivery of medicament is presented that has an elongated housing, a container mounted within the housing and adapted to contain liquid medicament, a stopper slidably arranged within said container, and a delivery mechanism comprising a resilient member, a plunger assembly having one end connected to the stopper and a second end being operably connected to the resilient member, a rotatable latch for releasably retaining the plunger assembly in a first position where the resilient member has an accumulated energy, where rotation of the latch releases the plunger assembly such that the accumulated energy is transferred to the plunger assembly for driving the stopper within the container whereby the medicament within said container is delivered to an injection site. After delivery of the medicament a rotator having a hard stop feature aligns with a rib on the protective shield to prevent retraction of the protective shield.

Abstract: An automated system for regulating a patient's blood glucose, including a blood glucose sensor, an insulin injection device, and a processing and control unit.

Abstract: Disclosed are techniques related to determination of adjustments to fluid delivery settings. The techniques may involve accessing an input meal size category, where the input meal size category is selected from among a plurality of meal size categories via a user interface; accessing a plurality of groups of historical meal events for a person, where each group of the plurality of groups is associated with a respective meal size category of the plurality of meal size categories and includes respective historical meal events for the person categorized in the respective meal size category; identifying a group, in the plurality of groups of historical meal events for the person, having an associated meal size category that matches the input meal size category; identifying a person-specific carbohydrate amount representative of the historical meal events in the identified group; and determining a bolus dosage value of insulin based on the person-specific carbohydrate amount.

Abstract: Disclosed herein are rapidly insertable central catheters (“RICCs”), RICC assemblies, and methods thereof. For example, a RICC can include a catheter tube, a suture wing disposed over a medial portion of the catheter tube, a hub coupled to a proximal portion of the catheter tube, and a number of extension legs extending from the hub. The catheter tube can include a first section in a distal portion of the catheter tube and a second section proximal of the first section. The suture wing can include a projection opposite a patient-facing side of the suture wing and a needle through hole through the projection. The needle through hole can be configured to accept a needle therethrough for insertion of the needle into a primary lumen of the catheter tube, which passes through a catheter-tube through hole through the suture wing. A method of the RICC can include using the RICC.

Abstract: An intrathecal drug delivery system configured to monitor one or more physiological conditions of the patient to look for opportunities to time medicament delivery to coincide with patient activity inferring heightened cerebrospinal fluid oscillations, thereby improving dispersion of the medicament within the intrathecal space of the patient. The intrathecal drug delivery system includes an implantable medical pump, one or more physiological sensors, and an external programmer configured to program the implantable medical pump with a treatment protocol specifying at least one period of time during which a specified quantity of medicament is to be administered during which the implantable medical pump utilizes data from the one or more physiological sensors to time delivery of the medicament.

Abstract: Closed-loop systems and methods are described herein for regulating a flow of medication being intermittently infused to a patient based on one or more vital signs. The dosage rate of the medication can be adjusted periodically as needed to ensure the patient's vital sign remains with a target range. Various safeguards can be used to ensure the safety and efficacy of the closed-loop systems and methods.

Abstract: The cell encapsulation system (CES) device is a device used for dermal, subdermal, muscle, tissue, or organ implantation into an individual (host) that is capable of being loaded with and carrying and containing exogenously introduced cells (encapsulated cells) that can produce relevant biochemicals (factors) and/or therapeutic molecules that can be transported to the host tissue while simultaneously not eliciting a significant host immune response (to the implanted device or to the encapsulated cells). The CES device provides a means of local and/or systemic, prolonged delivery of single or multiple factors and/or therapeutic molecules to alleviate, treat, or cure a variety of acute and chronic pathologies and ailments.

Abstract: A therapeutic agent delivery system (10) includes a housing (16) and a drive wheel (38) rotatably carried by the housing. A plunger rod (50) may be rotatable with the drive wheel relative to the housing from a first rotational configuration to a second rotational configuration. The plunger rod may be translatable relative to the housing from a first translational configuration to a second translational configuration. A plunger restraint (58) may maintain the plunger rod in the first translational configuration when the plunger rod is disposed in the first rotational configuration. The plunger restraint may permit the plunger rod to translate to the second translational configuration when the plunger rod is disposed in the second rotational configuration. A needle may move from a stowed configuration to a deployed configuration by the plunger rod when the plunger rod moves from the first translational configuration to the second translational configuration.